Abstracts tagged "autoimmune diseases"

Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB10 • ACR Convergence 2025
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Eric F. Morand¹, Cristina Arriens², Marilyn Pike³, Joan Merrill⁴, Victoria Werth⁵, Zahi Touma⁶, Razvan C. Ionitescu⁷, Masato Okada⁸, Ilias Kouris⁹, Yogita Kolekar¹⁰, Junyu Nie¹⁰, Venkat Renukuntla¹⁰, Thomas Wegman¹⁰ and Ronald van Vollenhoven¹¹, ¹Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Rheumatology, MedPharm Consulting, Inc, Bethesda, ⁴Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, ⁵University of Pennsylvania, Merion Station, Pennsylvania, ⁶University of Toronto, Toronto, Ontario, Canada, ⁷Medart Cliniq, Department of Rheumatology, Râmnicu Vâlcea, Romania, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Eli Lilly and Company Global, Basingstoke, United Kingdom, ¹⁰Bristol Myers Squibb, Princeton, ¹¹Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: There is a substantial unmet need for effective, well-tolerated therapies for patients with SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor…
Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Dong Xu¹, Shangzhu Zhang¹, Lin Qiao¹, Li Zhang¹, Wenxiang Wang², Lin Li², Binghua Xiao², Jing Zhang², Qing Zuraw³, Jianmin Fang² and Xiaofeng Zeng¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China (People's Republic), ²RemeGen Co., Ltd., Rheumatology, Yantai, China (People's Republic), ³Vor Biopharma Inc., Boston
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…
Abstract Number: LB14 • ACR Convergence 2025
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Rohit Aggarwal¹, David Korman², Margrit Wiesendanger³, Vikas Majithia⁴, Ellen De Langhe⁵, Marc Schmalzing⁶, Melissa Griffith⁷, Philipp Koehler⁸, Joanna Schiller⁸, Dimitrios Mougiakakos⁹, Mohamad Cherry¹⁰, Richard Nash¹¹, Jacques Azzi¹², Ernesto Ayala⁴, Peter Vandenberghe⁵, Max Topp⁶, Jonathan Gutman⁷, Eugen Feist¹³, Alisha Desai¹⁴, Alexis Melton¹⁴, Alice Wozniak¹⁴, San-San Ou¹⁴, Melissa Harnois¹⁴, Jerill Thorpe¹⁴, Praneeth Jarugula¹⁴, Takafumi Ide¹⁴, Ashley Koegel¹⁴ and Neil Kramer¹⁵, ¹University of Pittsburgh, Pittsburgh, Pennsylvania, ²Mountain Rheumatology, HCA HealthONE, Denver, Colorado, ³Icahn School of Medicine at Mount Sinai, New York, New York, ⁴Mayo Clinic Hospital, Jacksonville, Florida, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Clinical Immunology and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany, ⁹University Hospital Magdeburg, Magdeburg, Germany, ¹⁰Atlantic Health System, Morristown, New Jersey, ¹¹HealthOne Cares and Colorado Blood Cancer Institute, Denver, Colorado, ¹²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, ¹³Helios Vogelsang-Gommern Specialist Clinic, Gommern, Germany, ¹⁴Bristol Myers Squibb, Princeton, New Jersey, ¹⁵Overlook Medical Center and Atlantic Medical Group, Atlantic Health System, Morristown, New Jersey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases affecting muscles, skin, lungs, joints, and several other organs; many patients are refractory to available therapy,…
Abstract Number: 2350 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Upadacitinib (UPA) is a Janus Kinase inhibitor (JAKi) selective for JAK1, approved for the treatment of both Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA).…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…
Abstract Number: 1833 • ACR Convergence 2025
DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases
Dong ZHANG, Guangan Hu, Xiaodong Jiang, Quanju Zhao, Tainfei Hou, Zhengwang Sun, Mousheng Xu and Nan Bing, D²M Biotherapeutic, Inc, NATICK, MA
Background/Purpose: IL-12, via its p35 subunit, drives Th1-mediated pathology in autoimmune diseases. Genome-wide association studies (GWAS) suggested that IL12A encoding IL12p35 is associated with systemic…
Abstract Number: 1667 • ACR Convergence 2025
Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Zachary Daniel¹, Summia Afridi¹, Michael Allen² and Khoa Ngo¹, ¹Albany Medical College, Albany, NY, ²Albany Med, Albany, NY
Background/Purpose: Up to 30% of patients with incident pericarditis will develop recurrent pericarditis (RP), with severe impact on quality of life. More than 20% of…
Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…
Abstract Number: 1379 • ACR Convergence 2025
Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Biji T Kurien¹, Martha Tsaliki² and R Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OMRF, Oklahoma City, OK
Background/Purpose: Renal involvement in primary Sjögren’s disease (pSjD) is a well-known extraglandular manifestation with a prevalence of 5-14% in several studies. Mostly, it affects the…
Abstract Number: 1181 • ACR Convergence 2025
Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines
Robert Corty¹, Gul Karakoc¹, Ahmad Jawdat², Hui Yu³, Jonathan Mosley⁴, Michael Stein¹ and Vivian Kawai⁵, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alabama at Birmingham, Birmingham, ³University of Miami, Miami, ⁴UT Southwestern Medical Center, Dallas, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The tumor necrosis factor superfamily (TNFSF) includes 48 proteins involved in immune activation, inflammation, and cell death and represent an area of intense focus…
Abstract Number: 1080 • ACR Convergence 2025
Are Minority Populations Truly Vaccine Hesitant? A Provider-Based Approach to RSV Vaccine Uptake Suggests Otherwise.
pavana sakhamuri¹, Stephen Lindsey², Cathryn Leggio³ and Ellen Mire⁴, ¹LSUHSC, Dept of Rheumatology, Lafayette, LA, ²LSUHSC, Dept of Rheumatology, NEW ORLEANS, LA, ³University Medical center, NEW ORLEANS, LA, ⁴LSUHSC, Dept of Medicine, NEW ORLEANS, LA
Background/Purpose: Respiratory Syncytial Virus (RSV) is a leading cause of hospitalization and mortality in older adults and young children, particularly those with chronic illnesses or…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 0912 • ACR Convergence 2025
CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus
Roukaya Yaakoub, Diana Alzamareh, Alexander Bae William and Jennifer Barnas, university of rochester, rochester, NY
Background/Purpose: Autoimmune-associated B cells (ABCs) are increasingly recognized for their role in the pathogenesis of systemic lupus erythematosus (SLE), yet their developmental origins and specific…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…

1
2
3
…
101
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].